LONDON UK April 11, 2023 AposHealth®, a disruptive global company focused on revolutionising the treatment of musculoskeletal (MSK) conditions such as knee osteoarthritis (OA), has been awarded official guidance for recommended use of its flagship product, Apos®, by the National Institute for Health and Care Excellence (NICE).1 NICE recommends Apos® for patients with knee osteoarthritis (OA) who have tried and failed non-surgical standard care and are candidates for total knee replacement surgery who choose to avoid surgery. This evidence-based guidance was formed with the backing of an independent committee after reviewing over 25 publications representing the clinical and economic outcomes of over 3,500 patients.
Apos® is an at-home, non-invasive foot-worn device that looks like a typical trainer. It is clinically proven to reduce pain using the principles of biomechanics.2 It works through the placement of proprietary pods on the bottom of the device that offload pressure away from painful areas3 and retrain muscular coordination for healthy walking patterns.4 Patients wear their Apos® for approximately an hour a day while going about their regular routine and experience benefits even when not wearing the device.2
NICE’s thorough investigation has concluded that AposHealth’s treatment is clinically effective leading to a reduction in pain, improvement in function, and an overall increase in the quality of life for patients.1 The analysis also suggests that Apos® can provide a cost-saving per patient of £746 in Year 1 of treatment, increasing to £1,958 in Year 5, making it a highly cost-effective alternative to standard care.1 “This is fantastic news for patients with knee osteoarthritis, especially given the overwhelming backlog of patients waiting for surgery in the NHS,” says Sachin Gohil, Chief Commercial Officer at AposHealth UK. “With NICE recommending AposHealth, we can provide cost-effective, patient-focused care that leads to better outcomes and makes more efficient use of MSK services.”
“We are thrilled and grateful to NICE for their dedication to the process of helping healthcare providers make informed decisions about the adoption of innovative medical technologies,” says Cliff Bleustein, MD, MBA, President and CEO of AposHealth. “Adding Apos® to the knee OA care pathway is an important step that will enable many patients to receive a non-surgical intervention to treat their knee pain as an alternative option to surgery. Founders Avi Elbaz, MD and Amit Mor, MD state, “After extensive clinical trials and research, it gives us great happiness to know Apos® is recognized by NICE and has the potential to change the lives of so many patients in the UK and beyond.”
Apos® is available across the NHS through the NHS supply chain. For more information, visit AposHealth.co.uk.
To review NICE’s recommendation, see here: https://www.nice.org.uk/guidance/mtg76
- National Institute for Health and Care Excellence, https://www.nice.org.uk/guidance/mtg76
- Reichenbach S; et al. https://jamanetwork.com/journals/jama/fullarticle/2765729
- Haim, A; et al. https://www.sciencedirect.com/science/article/abs/pii/S0021929011006403
- Miles, C; et al. https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-020-03382-3
- Based on data captured at 3rd follow up appointment and is based on the commercial activity with National Health Service patients in the UK treated between 2019-2020 (N=106)